SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Firm”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech firm with two novel expertise platforms designed to supply aid for these struggling with extreme ache whereas defending towards abuse and overdose, introduced at present the Firm has engaged worldwide investor relations specialists MZ Group (“MZ”) to guide a complete strategic investor relations and monetary communications program throughout all key markets.
MZ Group will work carefully with Ensysce administration to develop and implement a complete capital markets technique designed to extend the Firm’s visibility all through the funding group. The marketing campaign will spotlight how Ensysce is in search of to enhance the protection of pharmaceuticals by making use of its two breakthrough, proprietary drug expertise platforms TAAP™ and MPAR™ which might be designed to stop opioid abuse and overdose. Ensysce’s lead TAAP opioid, PF614, which has been developed as abuse-resistance and Part 1 knowledge demonstrated as secure with out compromising on efficacy, is anticipated to be the Firm’s first product commercialized and producing income for ongoing packages. Ensysce has secured FDA Quick-Monitor Designation and is utilizing the 505(b)(2) regulatory pathway, which may considerably cut back the trial/regulatory danger and potential time and value to market.
MZ has developed a distinguished repute as a premier useful resource for institutional buyers, brokers, analysts and personal buyers. The agency maintains workplaces worldwide and was just lately ranked No. 7 on the planet in enterprise communication.
Shannon Devine, Managing Director at MZ North America, will advise Ensysce in all aspects of company and monetary communications, together with the coordination of roadshows and funding conferences throughout key cities and constructing model consciousness with monetary and social media shops.
Ted Haberfield, Chairman & President of MZ Group North America, commented, “Ensysce’s revolutionary abuse-resistant opioids are designed to fight prescription drug abuse, an epidemic and one of many quickest rising drug issues within the U.S. The worldwide opioids market is anticipated to develop to $29.8 billion in 2023, with multiple third of the U.S. inhabitants and 20-30% of the world inhabitants reporting persistent ache. That is pushed partly by an ageing inhabitants, because the prevalence of persistent ache will increase with the next incidence of age-related ailments together with most cancers, cardiovascular issues, weight problems and diabetes. On the similar time, the increasing use of opioids has triggered an increase of their abuse stemming from the will to extend the onset of euphoria, its depth, and its length. During the last yr greater than 200 individuals died within the U.S. every day after overdosing on opioids. Ensysce’s new class of ache merchandise create untapped worth which presents an thrilling alternative, and we look ahead to sharing this with our community of institutional, household workplaces and retail buyers.”
Shannon Devine added, “The TAAP™ and MPAR™ platforms created by Ensysce mix anti-abuse and anti-overdose expertise to create new lessons of pharmaceuticals which might be anticipated to be highly effective and secure for everybody. TAAP™ opioids are designed with a 2-step verification mechanism that can not be ‘cracked’ like abuse deterrent formulations, thus delivering a extremely efficient resolution to fight drug abuse. TAAP™ is just activated by trypsin, a digestive enzyme that exists solely within the intestine. Due to this fact crushing, inhaling or injecting it is not going to trigger the opioid to be launched quicker to provide pleasure or euphoria. It additionally chemically modifies the opioid, thereby eliminating the potential abuse by the affected person by means of bodily means. MPAR™ is a great anti-overdose platform that’s designed to guard sufferers from overdosing when it’s mixed with TAAP™ opioids. MPAR™ inhibits trypsin when an excessive amount of TAAP™ opioid is swallowed, inhibiting full activation and opioid launch, and subsequently, stopping overdose-related deaths. MPAR™ is just triggered by an overdose, blocking the extra doses consumed. Taken collectively, these drug platforms assist meet the unmet want of safer opioid choices for people affected by extreme ache.”
“Our pipeline of ache, habit, and ADHD candidates developed utilizing TAAP™ and MPAR™ proceed to progress,” stated Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. “Most just lately we introduced a important step in our path in the direction of FDA approval – the primary dosing within the Bioequivalence (BE) trial of the novel Trypsin Activated Abuse Protected (TAAP) Opioid, PF614. Moreover, within the fourth quarter of 2021, we efficiently accomplished a financing of $15 million that offered us with the required proceeds to proceed development of our lead medical trial packages. We’re persevering with to develop the following era of progressive options to fight the potential for opioid abuse and we look ahead to working with Shannon and your complete crew at MZ Group to speak the worth of our expertise for constructing long-term worth for our shareholders,” concluded Kirkpatrick.
For extra data on Ensysce, please go to the Firm’s web site at www.ensysce.com. To schedule a convention name with administration, please e-mail your request to ENSC@mzgroup.us or name Shannon Devine at 203-741-8811.
About MZ Group
MZ North America is the US division of MZ Group, a worldwide chief in investor relations and company communications. MZ offers progressive, personalized providers to home and multinational non-public and public corporations throughout all industries by means of a novel, fully-integrated “one-stop-shop” strategy. By delivering a complete suite of services by means of one level of contact, MZ provides providers to all related markets geared to serving to our shoppers construct a sustainable public model. MZ North America has a worldwide footprint with workplaces situated in New York, Chicago, San Diego, Aliso Viejo, Austin, Minneapolis, Taipei and São Paulo. For extra data, please go to www.mzgroup.us.
About Ensysce Biosciences
Ensysce Biosciences, San Diego, CA is a clinical-stage biotech firm utilizing its proprietary expertise platforms to develop safer pharmaceuticals. Leveraging its Trypsin-Activated Abuse Safety (TAAP) and Multi-Tablet Abuse Resistance (MPAR™) platforms, the Firm is within the strategy of growing a brand new class of highly effective, tamper-proof opioids that stop each drug abuse and overdoses. Ensysce’s merchandise are anticipated to supply safer choices to deal with extreme ache and help in stopping deaths attributable to opioid abuse, lowering the human and financial value. The platforms are coated by an intensive worldwide mental property portfolio for a big selection of prescription drug compositions. For extra data, please go to www.ensysce.com.
Ahead-Wanting Statements
Statements contained on this press launch that aren’t purely historic could also be deemed to be forward-looking statements for the needs of the secure harbor provisions underneath The Non-public Securities Litigation Reform Act of 1995 and different federal securities legal guidelines. With out limiting the foregoing, using phrases comparable to “could,” “intends,” “can,” “would possibly,” “will,” “anticipate,” “plan,” and different comparable expressions are meant to establish forward-looking statements. The product candidates mentioned are in clinic and never authorised and there will be no assurance that the medical packages will likely be profitable in demonstrating security and/or efficacy, that Ensysce is not going to encounter issues or delays in medical growth, or that any product candidate will ever obtain regulatory approval or be efficiently commercialized. All forward-looking statements are based mostly on estimates and assumptions by Ensysce’s administration that, though Ensysce believes to be affordable, are inherently unsure. All forward-looking statements are topic to dangers and uncertainties which will trigger precise outcomes to vary materially from people who Ensysce anticipated. As well as, Ensysce’s enterprise is topic to further dangers and uncertainties, together with amongst others, the initiation and conduct of preclinical research and medical trials; the timing and availability of knowledge from preclinical research and medical trials; expectations for regulatory submissions and approvals; potential security issues associated to, or efficacy of, Ensysce’s product candidates; the provision or business potential of product candidates; the flexibility of Ensysce to fund its continued operations, together with its deliberate medical trials; the dilutive impact of inventory issuances from our fundraising; and Ensysce’s and its companions’ means to carry out underneath their license, collaboration and manufacturing preparations. These statements are additionally topic to plenty of materials dangers and uncertainties which might be described in Ensysce’s most up-to-date quarterly report on Kind 10-Q and present reviews on Kind 8-Okay, which can be found, freed from cost, on the SEC’s web site at www.sec.gov. Any forward-looking assertion speaks solely as of the date on which it was made. Ensysce undertakes no obligation to publicly replace or revise any forward-looking assertion, whether or not on account of new data, future occasions or in any other case, besides as required underneath relevant regulation.
Ensysce Biosciences Firm Contact:
Lynn Kirkpatrick, Ph.D.
Chief Government Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Primary: 203-741-8811
ENSC@mzgroup.us
Supply: Ensysce Biosciences Inc.
